Within the GEN-COVID Multicenter Study, biospecimens from more than 1,000 SARS-CoV-2-positive individuals have thus far been collected in the GEN-COVID Biobank (GCB). Sample types include whole blood, plasma, serum, leukocytes, and DNA. The GCB links samples to detailed clinical data available in the GEN-COVID Patient Registry (GCPR). It includes hospitalized patients (74.25%), broken down into intubated, treated by CPAP-biPAP, treated with O2 supplementation, and without respiratory support (9.5%, 18.4%, 31.55% and 14.8, respectively); and non-hospitalized subjects (25.75%), either pauci- or asymptomatic. More than 150 clinical patient-level data fields have been collected and binarized according to the organs/systems primarily affected by COVID-19: heart, liver, pancreas, kidney, chemosensors, innate or adaptive immunity, and clotting system, for further statistics. Hierarchical Clustering analysis identified five main clinical categories: i) severe multisystemic failure with either thromboembolic or pancreatic variant; ii) cytokine storm type either severe with liver involvement or moderate; iii) moderate heart type either with or without liver damage; iv) moderate multisystemic involvement either with or without liver damage; v) mild either with or without hyposmia. GCB and GCPR are further linked to the GEN-COVID Genetic Data Repository (GCGDR), which includes data from Whole Exome Sequencing and high-density SNP genotyping. The data are available for sharing through the Network for Italian Genomes, within the COVID-19 dedicated section. The study objective is to systematize this comprehensive data collection and start identifying multi-organ involvement in COVID-19, defining genetic parameters for infection susceptibility within the population, and mapping genetically COVID-19 severity and clinical complexity among patients.

中文翻译：

---

采用系统的方法进行生物储库并分析遗传和临床数据以推进COVID-19研究

迄今为止，在GEN-COVID多中心研究中，已经从GEN-COVID生物库（GCB）中收集了1000多个SARS-CoV-2阳性个体的生物标本。样本类型包括全血，血浆，血清，白细胞和DNA。GCB将样品链接到GEN-COVID患者注册表（GCPR）中可用的详细临床数据。其中包括住院患者（74.25％），分为插管，CPAP-biPAP治疗，补充O2和无呼吸支持（分别为9.5％，18.4％，31.55％和14.8）；非住院或无症状的受试者（25.75％）。根据主要受COVID-19影响的器官/系统，已收集并二值化了150多个临床患者水平数据字段：心脏，肝脏，胰腺，肾脏，化学传感器，先天性或适应性免疫以及凝血系统，进一步统计。层次聚类分析确定了五个主要的临床类别：i）血栓栓塞性或胰腺变异性的严重多系统衰竭；ii）细胞因子风暴类型，严重或伴有肝脏受累或中度；iii）有或没有肝脏损害的中度心脏型；iv）有或没有肝损害的中度多系统受累；v）有或没有低渗的轻度。GCB和GCPR还与GEN-COVID遗传数据存储库（GCGDR）相关联，其中包括来自全外显子组测序和高密度SNP基因分型的数据。可以通过COVID-19专用部分中的“意大利基因组网络”共享数据。研究目标是将这些全面的数据收集系统化，并开始确定多器官参与COVID-19，